Pre-transplant testing that helps to ensure success has been essential to improve results in transplantation of human organs. Monitoring teh immune response post-transplant is also key.
Similar testing is being done for organs from pigs with differences in scope, reagents, and interpretation.
A purveyor of these services for human organ transplant sold for ~$1B in 2012 and a niche player in the market today is valued at $1B.
Pre-transplant testing that helps to ensure success has been essential to improve results in allotransplantation. Similar testing is being done in xenotransplantation with reagents that differ by species. These tests are also used post-transplantation to monitor for rejection. Tests on cell-free DNA popularized in allotransplantation are likely applicable, with differences, to xenotransplantation.
One Lambda corporation, the leader in tissue matching for allotransplantation, was sold to a larger testing concern for ~$1B in 2012. CareDx, a current leader in cell free DNA testing for signs of rejection, has a market cap of ~$1.5B currently. Xenotransplantation easily has a 10X volume potential over the current allotransplantation market.